mRNA Expression and Genetic Polymorphisms Affecting DRD3 (rs6280) and HTR2A (rs6313) in Bruxism

NCT06457646 — Unknown, 169 participants, University of Monastir

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT06457646
StatusUnknown
Study typeObservational
Enrollment169 (Estimated)
SponsorUniversity of Monastir (Other)
ConditionsBruxism
InterventionsGenetic polymorphism (Genetic)
Datesstart 2024-06-02 (estimated), primary completion 2024-12-15 (estimated), completion 2024-12-17 (estimated), first posted 2024-06-13, last updated 2024-06-13

Related Papers Related Patents Related Grants Related Experts
All trials for Bruxism All trials of Genetic polymorphism

-Summary

The goal of this observational study is to learn about the genetic factors influencing bruxism, a condition characterized by teeth grinding, in a group of participants. The main questions it aims to answer are:

* Is there a significant association between the rs6313 polymorphism of the HTR2A gene and bruxism?
* Is there a significant association between the rs6280 polymorphism of the DRD3 gene and bruxism?

Participants will:

Provide DNA samples for genotyping of the DRD3 (rs6280) and HTR2A (rs6313) polymorphisms.

Provide RNA samples to assess changes in the expression of HTR2A and DRD3. Researchers will compare the genetic data and RNA expression levels between individuals with bruxism and those without (controls) to see if there are significant genetic differences and expression changes associated with bruxism.

Expand all sections  ·  Collapse all

+Arms and interventions

  • Genetic polymorphism (Genetic): The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.

+Outcome measures

Primary outcomes

  • PCR-RFLP Analysis [1 year]

+Eligibility

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Inclusion Criteria:

* be above 18 years of age and have a confirmed diagnosis of bruxism

Exclusion Criteria:

* Systemic diseases,
* orofacial dysfunction,
* acute symptoms such as neurodegenerative diseases (specifically Parkinsons disease),
* Taking medication such as anxiolytics

+Publications

  • Results publication: Wieckiewicz M, Bogunia-Kubik K, Mazur G, Danel D, Smardz J, Wojakowska A, Poreba R, Dratwa M, Chaszczewska-Markowska M, Winocur E, Emodi-Perlman A, Martynowicz H. Genetic basis of sleep bruxism and sleep apnea-response to a medical puzzle. Sci Rep. 2020 May 4;10(1):7497. doi: 10.1038/s41598-020-64615-y. PMID 32367059
  • Results publication: Gassara Y, Foddha H, Chouchene S, Nasri S, Kallala R, Haj Khelil A, Hassin M, Ben Abdennebi H, Harzallah B. Analysis of genetic polymorphisms and mRNA expression of DRD3 and HTR2A in bruxism. BMC Oral Health. 2026 Jun 3. doi: 10.1186/s12903-026-08633-8. Online ahead of print. PMID 42237294